Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles
Eligible age
18–50 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this intervention study is to investigate the effects of daily egg intake on markers of gut health, high-density lipoprotein (HDL), metabolic, and immune cell profiles in adults with body mass indexes (BMI) in normal and obesity ranges. This study further aims to determine whether egg effects are associated with baseline gut microbiome profiles, and whether egg effects are different between males and females and by BMI status. The study will address the following objectives: Objective 1: Evaluate the effects of daily egg white vs. whole egg intake on gut health, microbiome, and metabolome profiles. Objective 2: Evaluate the effects of daily egg white vs. whole egg intake on HDL composition and function. Objective 3: Evaluate the effects of daily egg white vs. whole egg intake on immune profiles and function in culture (ex vivo). Participants will be asked to consume egg whites and whole eggs on a daily basis for 4-weeks each, and avoid eating eggs for a total of 8 weeks at different points in the study. Participants will be asked to complete surveys about dietary intake and physical activity, as well as provide blood and stool samples throughout the course of the study.
Sponsor: University of Connecticut
You may qualify if…
- ✓ 18-50 years old (at time of screening)
- ✓ Premenopausal status for women
- ✓ Body mass index (BMI) 18.5 to \< 25 kg/m2; or ³ 30 kg/m2 and \>30% and \>40% body fat for men and women, respectively
- ✓ Willing to consume whole eggs and egg whites provided during the study on a daily basis, and refrain from other eggs or egg-based foods and beverages during the study
- ✓ Do not fit any exclusion criteria
You may not qualify if…
- ✕ \<18 years old and ≥ 51 years old
- ✕ BMI \<18.5, 25-29.9, or body weight \< 110 pounds
- ✕ Experienced \>10% weight change in the past 4 weeks
- ✕ Elevated fasting glucose levels (fasting glucose higher than 126 mg/dL) and triglycerides greater than 500 mg/dL, or total cholesterol \< 120 mg/dL and HDL- cholesterol \< 15 mg/dL
- ✕ Self-reported and/or physician-diagnosed history of severe constipation, diabetes mellitus, coronary heart disease, stroke, renal or liver disease, cancer, eating disorders, certain severe and/or relapsing/remitting autoimmune, inflammatory, intestinal or metabolic diseases, chronic infections, scleroderma, blood clotting disorders, intravenous drug use, or current pregnancy or lactation, postmenopausal
- ✕ Allergy to eggs
- ✕ Implanted medical device (e.g., pacemaker) or other health condition that would prevent measurement of body composition by bioelectrical impedence
- ✕ Currently taking lipid-lowering medications (e.g., statins, fibrates), glucose-regulating medications, anti-inflammatory medications (e.g., NSAIDs, corticosteroids), or medications that primarily affect blood clotting (e.g., warfarin), long-term antibiotics or probiotics in the last 3 months or during the intervention
Where it's recruiting
Storrs
Source: ClinicalTrials.gov · NCT07844616 · last updated 2026-10-22